CAR T-Cell trial for rare lymphoma halted after just one patient
Disease control
Terminated
This study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to treatment. The goal was to see if it could make the cancer disappear. Only one person took part before the study was stopp…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated May 01, 2026 12:26 UTC